General MedicationsORALStandard
VYNDAMAX
TAFAMIDIS
Standard Dose
61MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview VYNDAMAX is listed in Drugs@FDA under application 212161 (NDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient TAFAMIDIS Form and strength CAPSULE;ORAL - 61MG Sponsor FOLDRX PHARMS Submission history Latest submission status date: 2023-10-17 00:00:00.
Structured Monograph
Clinical summary
Approval overview VYNDAMAX is listed in Drugs@FDA under application 212161 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient TAFAMIDIS Form and strength CAPSULE;ORAL - 61MG Sponsor FOLDRX PHARMS Submission history Latest submission status date: 2023-10-17 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.